Cargando…
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
Resistance to trastuzumab is frequently observed during the treatment of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancers. The aim of the present study was to determine if the phosphorylated proline-rich Akt substrate of 40 kDa (phospho-PRAS40(Thr246)), a novel...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301480/ https://www.ncbi.nlm.nih.gov/pubmed/25621052 http://dx.doi.org/10.3892/ol.2014.2744 |